Cannabics Pharmaceuticals Inc. (OTC-QB: CNBX) today Provides Shareholders Update for June 2017:
Cannabis has the potential of being a natural cancer attenuator comprising numerous active compounds which interact with human cells in a complex manner. Understanding the biological mechanism is a long and profound process, yet, utilizing diagnostic lab tests and clinical studies this potential can be unraveled.
Cannabics Pharmaceuticals engages in various technologies and studies that together create the knowledge of treating cancer patients with cannabis. For the understanding of the palliative aspects, dosages and side effects, we perform a clinical study on advanced cancer patients suffering from CACS. The results up-to-date have revealed the optimal dosages for an oral treatment of naïve patients avoiding side effects.
In the understanding of the anti-cancer properties we are currently analyzing a large body of data obtained from our high throughput screening research. Furthermore, we are gaining new data from our study on circulating tumor cells (CTC), currently focusing on the cannabinoids – CBD and CBDA. We are also engaged in creating software for big data analysis and its presentation to doctors.
The recent raising of $ 3 million enables us to create the platform for personalized treatment with cannabis that correlates to the genetics and biology of the patient and the cancer. To do so the company plans to market the diagnostic tests to cancer patients treated with cannabis, expand collaborations with biotech companies and harness new technologies that examine anti-tumor properties in our R&D lab in Israel.
About Cannabics Pharmaceuticals :
Cannabics Pharmaceuticals Inc. (CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Disclaimer:
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-K/A Report filed on March 15, 2017. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
